Andrew Wylie

Company: KSQ Therapeutics

Job title: Senior Vice President & Head of Oncology

Seminars:

Exploring KSQ-4279, a First in Class USP1 Inhibitor for the Treatment of Tumors with Defects in DNA Damage Repair 12:30 pm

Proprietary CRISPR screening platform identifies USP1 as a novel target that has a distinct, cancer-selective profile in comparison to other DDR targets that are often broadly cytotoxic Delve into the potent, selective USP1 inhibitor, KSQ-4279, is active in patient-derived xenograft models with DDR defects both as a monotherapy and in combination with PARP inhibitors Leveraging…Read more

day: Day Two